<DOC>
	<DOCNO>NCT02509845</DOCNO>
	<brief_summary>The purpose clinical study evaluate safety bacterial impact study drug ( C16G2 ) administer multiple oral gel dos adolescent adult dental subject .</brief_summary>
	<brief_title>Study Evaluate Safety Microbiology C16G2 Adolescent Adult Dental Subjects</brief_title>
	<detailed_description>The purpose clinical study evaluate safety microbiology C16G2 administer multiple oral gel dos adolescent adult dental subject . Subjects assign three study cohort receive 2 different volume C16G2 Gel Placebo . Prior commence enrollment subject 12-17 year age , safety cohort 4-8 adolescent subject receive 4 study drug administration Day 0 . A safety data review perform Medical Monitor Days 1 5 . If safety concern identify , enrollment adolescent subject receive 7 day study drug administration initiate Study Arms 1 &amp; 2 . Enrollment adult subject Study Arms 1 &amp; 2 may start Adolescent Safety Only Cohort initiate . Before dose study drug , eligible subject undergo professional dental prophylaxis Day 0 . Microbiology assess measure S. mutans total bacteria count .</detailed_description>
	<mesh_term>Dental Caries</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>1 . Adolescent Safety Only Cohort : Males female , 1217 year age , inclusive , time Assent Informed Consent Form sign . Study Arms 1 &amp; 2 : Males female , 1275 year age , inclusive , time Assent and/or Informed Consent Form sign 2 . Female subject childbearing potential , define surgically sterile least two ( 2 ) year postmenopausal , must agree use one follow form contraception screen last study visit : hormonal ( oral , implant , injection ) begin &gt; 30 day prior screen ; barrier ( condom , diaphragm , cervical cap spermicide ) ; intrauterine device ( IUD ) . Acceptable contraceptive option may also include abstinence , relationship sex partner partner vasectomy least six ( 6 ) month prior screen visit 3 . Male subject : willing use contraception abstain sexual activity begin first exposure study drug continue discharge study due completion Early Termination 4 . Healthy , determine Investigator , base medical dental history , concurrent illness , laboratory result , concomitant medication , oral cavity assessment , target physical examination ( extraoral , head neck ) Screening 5 . Have minimum six unrestored bicuspid molar ≤50 % molar bicuspids restoration , crown , sealant miss 6 . Demonstrated ability expectorate ≥2mL stimulate saliva 5 minute 7 . Have salivary S. mutans 1.0 x 10e5 CFUs/mL great Screening use MSB agar plat 8 . Willing refrain use nonstudy dentifrice nonstudy oral care product ( oral care rinse , fluoride product , etc . ) study 9 . Willing postpone elective dental procedure ( e.g. , dental cleaning ) Screening final posttreatment visit 10 . Willing able comply oral hygiene diet instruction 11 . Has dentition adequate custom dental tray gel application 12 . Able understand sign Assent and/or Informed Consent Form prior initiation study procedures 13 . Able communicate Investigator/study center personnel , understand comply study requirement , willing return protocolspecified visit appoint time 1 . Advanced periodontal disease 2 . Active caries lesion ( ) within 30 day prior study drug administration ( confirmed comprehensive caries examination include standard radiograph ) ; Note : Subjects present insipient , noncavitated lesion ( ) exclude 3 . Medical condition ( e.g. , artificial heart valve , history infective endocarditis , cardiac transplant valvular dysfunction , congenital heart disease total joint replacement ) antibiotic recommend prior dental visit and/or procedure 4 . Pathologic lesion oral cavity 5 . Full partial denture , orthodontic appliance , e.g. , night guard , permanent retainer 6 . Use systemic antibiotic , topical oral antibiotic , use drug , opinion Investigator could influence study outcome , within 30 day prior Screening 7 . Medical history indicate woman pregnant , breastfeeding/ lactate positive urine pregnancy test 8 . Participation clinical trial receipt nonFDA approve therapy within 30 day prior study drug administration 9 . Prior participation C16G2 clinical trial know receive C16G2 active gel mouth rinse 10 . Presence condition concurrent illness , opinion Investigator , would compromise normal immune function , interfere use study dentifrice oral care product , interfere ability comply study requirement , jeopardize safety subject validity study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>